"Rocky Mountain Cancer Centers (RMCC) is Colorado's largest and most comprehensive provider of cancer care with over 50 physicians, in nearly 20 community-based locations across the state. Our history is rich in forward thinking and best practice development. We were formed in 1992 when a group of independent medical oncology practices joined together to become a network of community-based clinic sites. This practice model has stood the test of time and continues to have proven clinical and economic benefit for patients, employers and payers today."

During the past decade, Rocky Mountain Cancer Centers conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 6 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rocky Mountain Cancer Centers" #1 sponsor was "Pfizer" with 6 trials, followed by "Gilead Sciences" with 2 trials sponsored, "AstraZeneca" with 1 trials sponsored, "Biotheranostics, Inc." with 1 trials sponsored and "Dendreon" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rocky Mountain Cancer Centers" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Iqvia Pty Ltd" with 1 trials as a collaborator and "Medivation, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Rocky Mountain Cancer Centers" are "Triple Negative Breast Cancer" (2 trials), "Advanced Breast Cancer" (1 trials), "Advanced Prostate Cancer" (1 trials), "BRCA 1 Gene Mutation" (1 trials) and "BRCA 2 Gene Mutation" (1 trials). Many other conditions were trialed in "Rocky Mountain Cancer Centers" in a lesser frequency.

Most popular intervention types in "Rocky Mountain Cancer Centers" are "Drug" (8 trials), "Biological" (3 trials), "Device" (1 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (3 trials), "Carboplatin" (2 trials), "Gemcitabine" (2 trials), "Pembrolizumab" (2 trials) and "Sacituzumab Govitecan-hziy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Rocky Mountain Cancer Centers" are 10 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Rocky Mountain Cancer Centers". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Rocky Mountain Cancer Centers, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Rocky Mountain Cancer Centers, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".